ULTRA-RARE CANCERThyroid CancerWHO 5th Edition Classification

Anaplastic Thyroid Carcinoma (ATC)

Ultra-Rare Malignancy (< 1 case per 1,000,000 / year) • Clinical Staging, Genomic Targets & Vetted Specialists

The most aggressive thyroid malignancy, in which thyroid cells lose all differentiated features. It is classified as stage IV by definition at diagnosis. Airway compromise is the immediate threat and is what dictates the first hours of management.

Request Rare Cancer Tumor Board Find NCI Treatment CentersAsk Vani AI Navigator

Emergent Referral AdvisoryImmediate Action

Certain rare malignancies progress rapidly or carry acute risk of airway obstruction, acute spinal compression, hydrocephalus, or biopsy-seeding. Do not perform needle biopsy or surgery outside of an NCI-designated specialty sarcoma or neuro-oncology unit without multidisciplinary tumor board review.

Report immediately to an emergency department or tertiary oncologist upon:

  • Stridor or any airway compromise - emergency
  • Neck mass doubling in size within weeks - same-week molecular testing
Who It Affects

Older adults, typically over 60; slight female predominance

Annual Incidence

Approximately 1-2 per million per year

Clinical Evidence Review

Last audited: 2026-08-13 against NCCN, ESMO, and WHO 5th ed. guidelines.

Clinical Presentation & Hallmark Symptoms

Presenting signs most frequently observed across clinical case series

Rapidly enlarging, hard neck mass over weeks
Hoarseness or voice change
Difficulty swallowing
Noisy or obstructed breathing (stridor)
Neck pain and fixed, non-mobile swelling

Genomic Profiling & Defining Molecular Lesions

Critical diagnostic fusions, somatic mutations, and therapeutic targets

Rare malignancies frequently depend on distinct oncogenic drivers rather than conventional environmental carcinogens. Comprehensive Next-Generation Sequencing (NGS comprehensive panel) and FISH/IHC are mandatory to establish the true diagnosis and screen for basket trial agents.

BRAF V600ETERT promoterTP53RASPIK3CANTRK/RET fusions

Standard-of-Care Treatment Protocol

Frontline and multimodal strategies established under international consensus guidelines

1

Urgent airway assessment and securing the airway where needed

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

2

BRAF/MEK inhibition (dabrafenib + trametinib) if BRAF V600E-mutated

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

3

Surgery where an R0/R1 resection is achievable

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

4

Concurrent chemoradiotherapy

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

5

Immunotherapy, including pembrolizumab in combination protocols

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

6

Neoadjuvant targeted therapy to convert unresectable to resectable disease

Administered in specialized high-volume oncology programs with subspecialty pathology and organ-preservation protocols.

Clinical Trial Advisory: For rare and ultra-rare malignancies, enrollment in an active clinical trial or expanded-access program is widely considered the preferred standard of care by ASCO and NCCN panels.

Prognosis & Disease Trajectory

Objective clinical outlook without false reassurance

Historically 3-6 months median survival. Molecularly guided therapy has changed this materially for the BRAF V600E-mutated subset, where neoadjuvant dabrafenib/trametinib followed by surgery has produced one-year survival substantially above historical rates.

Note: Statistics reflect cohort averages. Individual outcomes depend heavily on performance status, resectability, biomarker expression, and timely access to specialized tertiary care.

Active Research, Biomarkers & Clinical Trials

Novel investigational agents, phase I/II trials, and international rare disease consortia

Neoadjuvant targeted therapy followed by resection, RET and NTRK inhibitors in fusion-positive disease, and checkpoint inhibitor combinations are all in active study.

Need Help Matching to an Active Rare Cancer Trial?

ByOnco scans ClinicalTrials.gov, NCI trial networks, and institutional registries for open patient cohorts.

Request Trial Match
Expert Clinicians

Verified Specialists for Anaplastic Thyroid Carcinoma

Browse All Oncologists

Dr. Maria E. Cabanillas

Oncologic Endocrinologist

20+ yrs exp

MD Anderson Cancer Center

Houston, USA

Endocrine OncologyThyroid CancerATC
Vetted DirectoryConsult Specialist

Dr. Samantha Yang Peiling

Endocrinologist

15+ yrs exp

NCIS/NUH Singapore

Singapore, Singapore

Thyroid CancerEndocrinologyATC
Vetted DirectoryConsult Specialist

Prof. Martin Schlumberger

Oncologist

40+ yrs exp

Gustave Roussy

Paris, France

Thyroid CancersEndocrine OncologyATC
Vetted DirectoryConsult Specialist

Dr. Sanu P. Moideen

Head & Neck Oncosurgeon (ENT)

25+ yrs exp

Private Practice

Kerala, India

Head & Neck SurgeryThyroid CancerATC
Vetted DirectoryConsult Specialist
Hospital Network

Designated Cancer Centers with Dedicated Programs

Search All 72 NCI Centers

Memorial Sloan Kettering Cancer Center

NY

NCI-Designated Comprehensive Cancer Center

World-leading rare tumor board & pediatric solid tumor protocols

Proton TherapyCAR-T Cell TherapyRobotic Surgery
1,000+ Active Clinical TrialsView Center Profile

University of Texas MD Anderson Cancer Center

TX

NCI-Designated Comprehensive Cancer Center

Largest specialized rare cancer and sarcoma multidisciplinary program

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
1,200+ Active Clinical TrialsView Center Profile

Dana-Farber / Harvard Cancer Center

MA

NCI-Designated Comprehensive Cancer Center

Pioneering genomic molecular tumor boards & rare histologies

Proton TherapyCAR-T Cell TherapyPhase I Unit
1,100+ Active Clinical TrialsView Center Profile

Mayo Clinic Comprehensive Cancer Center

MN

NCI-Designated Comprehensive Cancer Center

High-volume surgical oncology & rare endocrine/neuroendocrine expertise

Proton TherapyCAR-T Cell TherapyCyberKnife SBRT
600+ Active Clinical TrialsView Center Profile

Frequently Asked Clinical Questions

Authoritative guidance on diagnosis, tumor boards, genomic markers, and care options

Related Rare Malignancies in Catalog

ultra-rare

Malignant Rhabdoid Tumor

ultra-rare

Hepatosplenic T-cell Lymphoma (HSTCL)

ultra-rare

T-cell Prolymphocytic Leukemia (T-PLL)

ultra-rare

Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)

Independent Tumor Board Review

Facing a Diagnosis of Anaplastic Thyroid Carcinoma?

Rare cancers demand rare expertise. Connect your medical records to US NCI-fellowship trained oncologists, subspecialist pathologists, and active clinical trial investigators within 12 to 72 hours.

Upload Scans for Second Opinion Schedule Virtual Teleconsult